Heat shock protein-90-induced microglial clearance of exogenous amyloid-β1-42 in rat hippocampus in vivo

Neuroscience Letters

Volumn 344, Issue 2, 2003, Pages 87-90

  Takata, Kazuyuki ^a   Kitamura, Yoshihisa ^a   Tsuchiya, Daiju ^a   Kawasaki, Toshiyuki ^a   Taniguchi, Takashi ^a   Shimohama, Shun ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid (1 42); Heat shock protein 90; In vivo; Intrahippocampal injection; Microglial clearance; Rat

Indexed keywords

AMYLOID BETA PROTEIN; HEAT SHOCK PROTEIN 90;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HIPPOCAMPUS; IN VIVO STUDY; MALE; MICROGLIA; MICROINJECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0038356802     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00447-6     Document Type: Review

References (19)

1. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
2. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.-H., Abramowski D., Sturchler-Pierrat C., Sommer B., Staufenbiel M., Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. USA. 96:1999;14088-14093.
3. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.-C., Paul S.M., Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:2001;8850-8855.
4. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M.B., Stricker B.H.C. Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345:2001;1515-1521.
5. 1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6:2000;143-150.
6. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., Gordon M.N. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing non-steroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22:2002;2246-2254.
7. Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. Microglial activation and amyloid-β clearance induced by exogenous heat-shock proteins, FASEB J (February 25, 2002) 10.1096/fj.01-0530fje, Summary. FASEB J. 16:2002;601-603.
8. Kakimura J., Kitamura Y., Taniguchi T., Shimohama S., Gebicke-Haerter P.J. BiP/GRP78-induced production of cytokines and uptake of amyloid-β(1-42) peptide in microglia. Biochem. Biophys. Res. Commun. 281:2001;6-10.
9. Kaneko I., Tutumi S. Matters arising: Conformations of β-amyloid in solution. J. Neurochem. 68:1997;438-439.
10. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Hsiao Ashe K., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;372-381.
11. Kettenmann H., Ransom B.R. Neuroglia. 1995;Oxford University Press, New York and Oxford.
12. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
13. Paresce D.M., Gohsh R.N., Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron. 17:1996;553-565.
14. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd Edition:1986;Academic Press, North Ryde, Australia.
15. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273:1998;32730-32738.
16. Schenk D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3:2002;824-828.
17. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:(Suppl.):1999;A23-A31.
18. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:2000;1489-1499.
19. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., Mann D.M.A., Hyman B.T., Iwatsubo T. Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157:2000;331-339.